MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer.
暂无分享,去创建一个
C. Liang | Zaiyi Liu | Cheng Lu | Zhenwei Shi | Chunling Liu | J. Qu | Zeyan Xu | Xiaomei Huang | Chu Han | Chen Liu | Huan Lin | Ziliang Cheng | Junyue Shen | Yan-hai Cui | Xiaobo Chen
[1] Xiaodong Yang,et al. Pretreatment DCE-MRI-Based Deep Learning Outperforms Radiomics Analysis in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer , 2022, Frontiers in Oncology.
[2] Yasunobu Nohara,et al. Explanation of Machine Learning Models Using Shapley Additive Explanation and Application for Real Data in Hospital , 2021, Comput. Methods Programs Biomed..
[3] M. Salvatore,et al. Assessment and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Imaging Modalities and Future Perspectives , 2021, Cancers.
[4] H. Yao,et al. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study , 2021, EBioMedicine.
[5] G. Christofori,et al. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression , 2021, British Journal of Cancer.
[6] D. Berry,et al. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL , 2020, npj Breast Cancer.
[7] D. Berry,et al. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. , 2020, JAMA oncology.
[8] Anant Madabhushi,et al. MRQy: An Open-Source Tool for Quality Control of MR Imaging Data , 2020, ArXiv.
[9] Maciej A. Mazurowski,et al. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set , 2018, Breast Cancer Research and Treatment.
[10] Ruijiang Li,et al. Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. , 2018, Radiology.
[11] Vivek Verma,et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy , 2018, Breast Cancer Research and Treatment.
[12] A. Shaw,et al. Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.
[13] A. Stuckey,et al. ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer. , 2017, Journal of the American College of Radiology : JACR.
[14] Stefan Leger,et al. Image biomarker standardisation initiative version 1 . 4 , 2016, 1612.07003.
[15] Chris Bakal,et al. Microenvironmental Heterogeneity Parallels Breast Cancer Progression: A Histology–Genomic Integration Analysis , 2016, PLoS medicine.
[16] Charles Swanton,et al. Clinical management of breast cancer heterogeneity , 2015, Nature Reviews Clinical Oncology.
[17] D G Altman,et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement , 2015, The British journal of surgery.
[18] Stephen M. Moore,et al. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository , 2013, Journal of Digital Imaging.
[19] Jayaram K. Udupa,et al. New variants of a method of MRI scale standardization , 2000, IEEE Transactions on Medical Imaging.